国产吉西他滨联合顺铂方案治疗晚期非小细胞肺癌临床观察  

Clinical Study of Homemade Gemcitabine plus Cisplatin Regimen in the Treatment of Advanced Non-Small Cell Lung Cancer

作　　者：张怡梅[1] 朱严冰[1] 倪海英[1] 孟冀昌[1] 苏同义[1] 

机构地区：[1]解放军白求恩国际和平医院肿瘤科,河北石家庄050082

出　　处：《肿瘤基础与临床》2008年第2期124-126,共3页journal of basic and clinical oncology

摘　　要：目的观察国产吉西他滨（泽菲）联合顺铂方案治疗晚期非小细胞肺癌的疗效与毒副反应。方法共36例接受下述联合方案化疗至少2周期。泽菲1000～1250mg／m^2，d1,8；顺铂25～30mg／m^2，d1-3，21d为1周期。每化疗2周期后评价疗效。每周期化疗结束后均填写药物毒性观察表。结果总有效率为38．9％，初治患者有效率为50．0％，复治患者有效率为25．0％，初治与复治患者疗效差异有统计学意义。骨髓抑制为GP方案主要的毒副反应，以血小板减少为主，有69．4％患者出现血小板减少（Ⅲ度以上占28．9％）。结论国产吉西他滨联合顺铂方案治疗晚期非小细胞肺癌疗效佳、毒副反应小。血小板减少为限制吉西他滨按时继续用药的主要原因。Objective To study the effect and toxicity of GP regimen in advanced and relapsed non-small cell lung cancer （ NSCLC）. Methods Thirty-six eases with NSCLC received chemotherapy as follows at least 2 cycles, gemeitabine （GEM） 1 000 - 1 250 mg/m^2 i. v on day 1 and 8, eisplatin （DDP） 25 mg/m^2 i. v on days 1 to 3, repeated every 21 days, after 2 cycles for evaluating response, and after 1 cycle for toxieity. Results The all over response rate（ CR ＋ PR） was 38.9% , The response rate had differenee between first therapy and repeated therapy. The response rate of first therapy was 50.0% , the response rate of repeated therapy was 25.0% . Myelosuppression was the main toxieity, thromboeytopenia was the main in myelosuppression. Thromboeytopenia oeeurred in 69.4% patients（grade m and 1g thromboeytopenia occurred in 28.9% patients）. Conclusions GP is an effeetive and acceptable regimen for advanced and relapsed NSCLC. The main dose limiting toxieity was thromboeytopenia.

关 键 词：非小细胞肺癌 化疗 吉西他滨 顺铂 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]